valproic acid has been researched along with Anxiety Neuroses in 29 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 9.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| " Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder." | 5.20 | A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. ( Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Zarate, CA, 2015) |
| "Pediatric epilepsy is a common, chronic, and challenging physical illness for children and their families." | 2.46 | Psychiatric concerns in pediatric epilepsy. ( Bujoreanu, IS; DeMaso, DR; Ibeziako, P, 2010) |
| "Agents introduced for the treatment of epilepsy have also been usedsimultaneously for psychiatric indications." | 2.43 | [Anticonvulsants treatment of psychiatric disorder in elderly patients]. ( Bidzan, L, 2006) |
| "There are clear connections between migraine and psychiatric disorders and the attending physician should have them in mind." | 2.42 | [Migraine and psychiatric disorders]. ( Fasmer, OB; Oedegaard, KJ, 2004) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "Topiramate was more likely prescribed for those with comorbid headache or migraine (incident: 335 of 1251 [26." | 1.51 | Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy. ( Faught, E; Fishman, J; Kalilani, L; Kim, H; Thurman, DJ, 2019) |
| "For the management of bipolar depression, new data support quetiapine monotherapy as a first-line option." | 1.33 | Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. ( Beaulieu, S; Kennedy, SH; MacQueen, G; McIntyre, RS; O'Donovan, C; Parikh, SV; Sharma, V; Yatham, LN, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.90) | 18.7374 |
| 1990's | 5 (17.24) | 18.2507 |
| 2000's | 11 (37.93) | 29.6817 |
| 2010's | 9 (31.03) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Colijn, MA | 1 |
| Thornton, AM | 1 |
| Humphrey, RM | 1 |
| Kerr, DM | 1 |
| Finn, DP | 1 |
| Roche, M | 1 |
| Kim, H | 1 |
| Faught, E | 1 |
| Thurman, DJ | 1 |
| Fishman, J | 1 |
| Kalilani, L | 1 |
| Hlal, H | 1 |
| Barrimi, M | 1 |
| Kettani, N | 1 |
| Rammouz, I | 1 |
| Aalouane, R | 1 |
| San Miguel López de Uralde, SM | 1 |
| Prieto Peraita, M | 1 |
| Blanco Bengoechea, EJ | 1 |
| Ionescu, DF | 1 |
| Luckenbaugh, DA | 1 |
| Niciu, MJ | 1 |
| Richards, EM | 1 |
| Zarate, CA | 1 |
| Barker-Haliski, ML | 1 |
| Heck, TD | 1 |
| Dahle, EJ | 1 |
| Vanegas, F | 1 |
| Pruess, TH | 1 |
| Wilcox, KS | 1 |
| White, HS | 1 |
| Bujoreanu, IS | 1 |
| Ibeziako, P | 1 |
| DeMaso, DR | 1 |
| Estabrook, KR | 1 |
| Pheister, M | 1 |
| Whittle, N | 1 |
| Schmuckermair, C | 1 |
| Gunduz Cinar, O | 1 |
| Hauschild, M | 1 |
| Ferraguti, F | 1 |
| Holmes, A | 1 |
| Singewald, N | 1 |
| Kuriyama, K | 1 |
| Honma, M | 1 |
| Yoshiike, T | 1 |
| Kim, Y | 1 |
| Stahl, SM | 1 |
| Fasmer, OB | 1 |
| Oedegaard, KJ | 1 |
| Beresford, TP | 1 |
| Arciniegas, D | 1 |
| Clapp, L | 1 |
| Martin, B | 1 |
| Alfers, J | 1 |
| Yatham, LN | 2 |
| Kennedy, SH | 2 |
| O'Donovan, C | 2 |
| Parikh, S | 1 |
| MacQueen, G | 2 |
| McIntyre, R | 1 |
| Sharma, V | 2 |
| Silverstone, P | 1 |
| Alda, M | 1 |
| Baruch, P | 1 |
| Beaulieu, S | 2 |
| Daigneault, A | 1 |
| Milev, R | 1 |
| Young, LT | 1 |
| Ravindran, A | 1 |
| Schaffer, A | 1 |
| Connolly, M | 1 |
| Gorman, CP | 1 |
| de Araujo Filho, GM | 1 |
| Pascalicchio, TF | 1 |
| Lin, K | 1 |
| Sousa, PS | 1 |
| Yacubian, EM | 1 |
| Parikh, SV | 1 |
| McIntyre, RS | 1 |
| Bidzan, L | 1 |
| Aliyev, NA | 1 |
| Aliyev, ZN | 1 |
| Arnold, G | 1 |
| Schuh-Hofer, S | 1 |
| Meldrum, B | 1 |
| Baetz, M | 1 |
| Bowen, RC | 1 |
| Schatzberg, AF | 1 |
| DeBattista, C | 1 |
| Davis, LL | 1 |
| Ryan, W | 1 |
| Adinoff, B | 1 |
| Petty, F | 1 |
| Lum, M | 1 |
| Fontaine, R | 2 |
| Elie, R | 1 |
| Ontiveros, A | 1 |
| Primeau, F | 1 |
| Beauclair, L | 1 |
| Coplan, JD | 1 |
| Gorman, JM | 1 |
| Roy-Byrne, PP | 1 |
| Ward, NG | 1 |
| Donnelly, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study[NCT00400088] | Phase 3 | 2 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Recruitment difficulties) | ||
| Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety[NCT00590265] | 50 participants (Anticipated) | Interventional | 2008-01-31 | Active, not recruiting | |||
| Prophylactic Use of Immediate Postpartum Sertraline to Prevent Postpartum Depression: A Double Blind Randomized Placebo Controlled Trial[NCT02235064] | 2 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Low recruitment, completion of funding cycle) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
The Antidepressant Side-Effect Checklist (ASEC) was employed to detect any adverse reaction to treatment regimens (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 1 |
"Patients met with single psychiatrist (co-investigator), blinded to group assignment, who evaluated the patient using Edinburgh Postpartum Depression Screen, Hamilton Depression Rating Scale, Global Assessment of Functioning Scale, and clinical assessment~0 = No postpartum depression up to 12 weeks following discharge from hospital~1 = Postpartum depression up to 12 weeks following discharge from hospital" (NCT02235064)
Timeframe: Discharge from hospital to 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 0 |
| Placebo | 0 |
(NCT02235064)
Timeframe: 12 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 4734 |
(NCT02235064)
Timeframe: 4 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 3033 |
| Placebo | 2750 |
(NCT02235064)
Timeframe: 8 weeks postpartum
| Intervention | Grams (Mean) |
|---|---|
| Sertraline | 5301 |
| Placebo | 3685 |
13 reviews available for valproic acid and Anxiety Neuroses
| Article | Year |
|---|---|
The characterization of psychotic symptoms in succinic semialdehyde dehydrogenase deficiency: a review.
Topics: Adolescent; Age of Onset; Aggression; Amino Acid Metabolism, Inborn Errors; Anticonvulsants; Anxiety | 2020 |
Psychiatric concerns in pediatric epilepsy.
Topics: Adolescent; Amines; Anxiety Disorders; Bipolar Disorder; Child; Child, Preschool; Cyclohexanecarboxy | 2010 |
Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA.
Topics: Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Carbamazepine; Fructose; GABA Agonists; gam | 2004 |
[Migraine and psychiatric disorders].
Topics: Antidepressive Agents; Antimanic Agents; Anxiety Disorders; Comorbidity; Humans; Mental Disorders; M | 2004 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
[Anticonvulsants treatment of psychiatric disorder in elderly patients].
Topics: Aged; Anticonvulsants; Anxiety Disorders; Bipolar Disorder; Carbamazepine; Epilepsy; Humans; Mental | 2006 |
[Comorbidities in migraine patients].
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants; Anxiety Disorders; Carotid Artery, | 2007 |
ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disorder; Breast Feed | 2008 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
Phenomenology and treatment of agitation.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 1999 |
Comprehensive review of the psychiatric uses of valproate.
Topics: Anticonvulsants; Antimanic Agents; Anxiety Disorders; Bipolar Disorder; Depressive Disorder, Major; | 2000 |
Treatment of anxiety disorder in patients with mood disorders.
Topics: Antidepressive Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Depressive Disorder; Humans; L | 1990 |
Valproate in anxiety and withdrawal syndromes.
Topics: Adult; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Ethanol; Humans; Hypnotics and | 1989 |
6 trials available for valproic acid and Anxiety Neuroses
| Article | Year |
|---|---|
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
Topics: Adult; Affect; Anxiety; Anxiety Disorders; Bipolar Disorder; Cross-Over Studies; Depression; Double- | 2015 |
Valproic acid but not D-cycloserine facilitates sleep-dependent offline learning of extinction and habituation of conditioned fear in humans.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Cycloserine; Excitatory Amino Acid Agonists; Extincti | 2013 |
Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study.
Topics: Acute Disease; Adult; Anticonvulsants; Anxiety Disorders; Azerbaijan; Diagnostic and Statistical Man | 2008 |
Probable interaction of sodium divalproex with benzodiazepines.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Double-Blind Method; Drug Interactio | 1991 |
Valproic acid and panic disorder.
Topics: Adult; Anxiety Disorders; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administr | 1990 |
Valproate in anxiety and withdrawal syndromes.
Topics: Adult; Anticonvulsants; Anxiety Disorders; Clinical Trials as Topic; Ethanol; Humans; Hypnotics and | 1989 |
11 other studies available for valproic acid and Anxiety Neuroses
| Article | Year |
|---|---|
Increasing Endocannabinoid Tone Alters Anxiety-Like and Stress Coping Behaviour in Female Rats Prenatally Exposed to Valproic Acid.
Topics: Animals; Anxiety; Anxiety Disorders; Autistic Disorder; Behavior, Animal; Disease Models, Animal; En | 2021 |
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Anxiety Disorders; Comorbidity; Dissociative Disorders; Epilepsi | 2019 |
["Factitious disorder and skin picking: Clinical approach". A case report].
Topics: Alprazolam; Anxiety Disorders; Comorbidity; Diagnosis, Differential; Disruptive, Impulse Control, an | 2014 |
[Pulmonary eosinophilia associated with valproic acid].
Topics: Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Anxiety Disorders; Bronchoalveolar Lavage Flu | 2015 |
Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy.
Topics: Animals; Anticonvulsants; Anxiety Disorders; Behavior, Animal; Body Weight; Chi-Square Distribution; | 2016 |
A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone.
Topics: Adult; Anti-Anxiety Agents; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disor | 2012 |
Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Benzhydryl Compounds; Deep Brain Stimulation; Disea | 2013 |
Reduction of affective lability and alcohol use following traumatic brain injury: a clinical pilot study of anti-convulsant medications.
Topics: Adult; Alcoholism; Anticonvulsants; Anxiety Disorders; Brain Injuries; Carbamazepine; Female; Humans | 2005 |
Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate.
Topics: Adolescent; Anticonvulsants; Anxiety Disorders; Cross-Sectional Studies; Depressive Disorder; Female | 2006 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Bipo | 2006 |
Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy.
Topics: Adolescent; Adult; Affect; Aged; Agoraphobia; Anxiety Disorders; Bipolar Disorder; Cognitive Behavio | 1998 |